Radcliffe Capital Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Radcliffe Capital Management’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-38,927	Closed	-$27K	–	900
2022 Q3	$27K	Sell	38,927 -16,765	-30%	-$2K	﹤0.01%	1187
2022 Q2	$81K	Hold	55,692	–	–	﹤0.01%	1236
2022 Q1	$562K	Sell	55,692 -25,205	-31%	-$21.3K	0.01%	1102
2021 Q4	$632K	Sell	80,897 -92,951	-53%	-$171K	0.02%	950
2021 Q3	$1.75M	Sell	173,848 -1,152	-0.7%	-$823	0.05%	519
2021 Q2	$1.74M	Hold	175,000	–	–	0.05%	550
2021 Q1	$1.72M	Buy	+175,000	New	+$182K	0.07%	474

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Radcliffe Capital Management's SABSW Position: Q4 2022 in Review

Radcliffe Capital Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2022, closing a stake of 38,927 shares — an estimated $27K sold.

Radcliffe Capital Management first reported a position in SABSW in Q1 2021 and held it in 7 quarters. The position peaked at $1.75M in Q3 2021. 13 funds tracked by Wall St. Rank hold SABSW as of Q4 2022.

Radcliffe Capital Management reported no remaining SAB Biotherapeutics Warrant position as of Q4 2022 after selling out during the quarter.
Radcliffe Capital Management sold 38,927 SAB Biotherapeutics Warrant shares in Q4 2022, an estimated $27K.
Radcliffe Capital Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 7 quarters.
Radcliffe Capital Management's SAB Biotherapeutics Warrant position peaked at $1.75M in Q3 2021.
13 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2022.

Based on Radcliffe Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.